NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).

Despite Altimmune, Inc.'s sharp selloff, I believe the market overreacted to pemvidutide's Phase IIb MASH data, which showed meaningful liver improvements and strong safety. The modest weight loss in MASH patients is not a dealbreaker, as this population is metabolically complex and prior trials in obesity showed competitive efficacy. Pemvidutide's MASH results compare favorably to the only approved drug, Rezdiffra, and could support accelerated approval if efficacy holds in Phase III.

Altimmune, Inc.'s pemvidutide met the primary endpoint of MASH resolution in phase 2b IMPACT study which sets it on a continued development path going forward. The short 24-week trial duration likely limited fibrosis results; longer studies could achieve statistical significance with this endpoint supporting a continued path for phase 3 development. Pemvidutide uniquely delivers both MASH resolution and weight loss, with the lowest adverse event-related discontinuation rates, giving it strong competitive advantages.

ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) complied with federal securities laws. On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), revealing that the trial did not demonstrate statistical significance for the endpoint of improving fibrosis while not worsening MASH. Following this news, the price of the Company's stock dropped.

Shares of Altimmune Inc (NASDAQ:ALT) tumbled 55% on Thursday after the company reported mixed results from a mid-stage trial of its experimental drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The Phase 2b study met one of its primary endpoints, with pemvidutide achieving statistically significant resolution of MASH without worsening of fibrosis at 24 weeks.

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease.

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 26, 2025 at 8:30 am ET GAITHERSBURG, Md., June 26, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced positive topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.